shutterstock_1523551736_frantic00
Frantic00 / Shutterstock.com
25 August 2020Big PharmaRobert Stephen and Gareth Morgan

Why Santen ends Neurim-style SPCs

The July 9 Santen decision ( C-673/18) from the Court of Justice of the European Union (CJEU) resolves the issues that arose from the earlier Neurim decision ( C-130/11) issued by the same court. Essentially, and unusually, the CJEU reversed its own earlier decision.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.